AU2005336924A1 - Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists - Google Patents

Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists Download PDF

Info

Publication number
AU2005336924A1
AU2005336924A1 AU2005336924A AU2005336924A AU2005336924A1 AU 2005336924 A1 AU2005336924 A1 AU 2005336924A1 AU 2005336924 A AU2005336924 A AU 2005336924A AU 2005336924 A AU2005336924 A AU 2005336924A AU 2005336924 A1 AU2005336924 A1 AU 2005336924A1
Authority
AU
Australia
Prior art keywords
substituted
cancer
hif
adenosine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005336924A
Other languages
English (en)
Inventor
Pier Giovani Baraldi
Pier Andrea Borea
Edward Leung
Stephen Maclennan
Stefania Merighi
Allan Moorman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King Pharmaceuticals Research and Development Inc
Original Assignee
King Pharmaceuticals Research and Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Research and Development Inc filed Critical King Pharmaceuticals Research and Development Inc
Publication of AU2005336924A1 publication Critical patent/AU2005336924A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2005336924A 2004-11-22 2005-11-22 Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists Abandoned AU2005336924A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63055704P 2004-11-22 2004-11-22
US60/630,557 2004-11-22
PCT/US2005/042551 WO2007040565A2 (en) 2004-11-22 2005-11-22 Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists

Publications (1)

Publication Number Publication Date
AU2005336924A1 true AU2005336924A1 (en) 2007-04-12

Family

ID=37906593

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005336924A Abandoned AU2005336924A1 (en) 2004-11-22 2005-11-22 Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists

Country Status (6)

Country Link
EP (1) EP1827445A2 (de)
JP (1) JP2008520746A (de)
AU (1) AU2005336924A1 (de)
CA (1) CA2586420A1 (de)
IL (1) IL183307A0 (de)
WO (1) WO2007040565A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (de) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
EP1797881B1 (de) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
EP2281901B1 (de) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Pharmazeutische anti-tumor Zusammensetzung mit Angiogeneseinhibitoren
EP2036557B1 (de) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumorales mittel gegen schilddrüsenkrebs
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
BRPI0921257A2 (pt) * 2008-11-14 2016-02-23 Bayer Schering Pharma Ag composto de arila heterociclicamente subsittuidos como inibidores hif
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
WO2014153363A1 (en) * 2013-03-18 2014-09-25 Northeastern University Method for generation of broadly neutralizing anti-pathogen antibodies
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
WO2021028382A1 (en) 2019-08-12 2021-02-18 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
WO2022029063A1 (en) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114574580B (zh) * 2022-02-14 2022-11-29 山东大学 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
WO2007040565A3 (en) 2009-04-16
EP1827445A2 (de) 2007-09-05
JP2008520746A (ja) 2008-06-19
CA2586420A1 (en) 2007-04-12
WO2007040565A2 (en) 2007-04-12
IL183307A0 (en) 2008-04-13
WO2007040565A9 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
AU2005336924A1 (en) Enhancing treatment of cancer and HIF-1 mediated disoders with adenosine A3 receptor antagonists
US20060204502A1 (en) Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists
US10231982B2 (en) System and method for diagnosis and treatment
KR102356433B1 (ko) 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법
JP7019422B2 (ja) 癌を治療するための方法
K Kontos et al. Apoptosis-related BCL2-family members: Key players in chemotherapy
JP6957650B2 (ja) 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、１−［４−ブロモ−５−［１−エチル−７−（メチルアミノ）−２−オキソ−１，２−ジヒドロ−１，６−ナフチリジン−３−イル］−２−フルオロフェニル］−３−フェニルウレアおよびアナログの使用
JP2022034068A (ja) 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
TW201242601A (en) Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
KR20160085365A (ko) 암 치료를 위한 병용 요법
JP2017521396A (ja) 癌のための併用療法
Visco et al. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines
CN114727996A (zh) 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
CN112512527A (zh) 恩扎妥林和btk抑制剂的组合及其用途
CN113164415A (zh) 依拉司群和阿贝西利在患乳腺癌女性中的联合应用
CN110996955A (zh) 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
JP2022524047A (ja) 効力を判定するための方法

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period